Providing Regulatory Support in China for a New Compound

A small-to mid-size pharmaceutical company in India was developing a new combination treatement for complicated urinary tract infection. They were starting studies in the U.S. and EU but also wanted to evaluate their treatment in China with a Phase III trial. They needed an experience partner and chose Labcorp Drug Development to help support their efforts. This case study shares how Labcorp provided a regulatory strategy and facilitated interactions with the National Medical Products Administration (NMPA) in China.